MedTrace Logo

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02588612 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-09-05

Study results available
· View outcomes & findings →

Summary

This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.

Conditions

  • Neoplasms

Interventions

DRUG

letetresgene autoleucel (GSK3377794)

letetresgene autoleucel (GSK3377794) as an IV infusion.

DRUG

Cyclophosphamide

Cyclophosphamide will be used as a lymphodepleting chemotherapy.

DRUG

Fludarabine

Fludarabine will be used as a lymphodepleting chemotherapy.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2020-08-10
Completion
2020-08-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588612 on ClinicalTrials.gov